Opus Genetics, Inc.
IRD
$0.865
$0.00430.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.99M | 8.38M | 16.45M | 19.01M | 19.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.99M | 8.38M | 16.45M | 19.01M | 19.05M |
| Cost of Revenue | 21.54M | 18.46M | 12.97M | 12.94M | 13.80M |
| Gross Profit | -10.55M | -10.08M | 3.48M | 6.07M | 5.25M |
| SG&A Expenses | 18.22M | 14.20M | 13.36M | 14.34M | 11.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.07M | 37.86M | 31.53M | 31.15M | 29.61M |
| Operating Income | -34.07M | -29.47M | -15.08M | -12.14M | -10.56M |
| Income Before Tax | -57.53M | -27.19M | -14.09M | -11.29M | -9.97M |
| Income Tax Expenses | -- | -2.00K | 12.00K | 12.00K | 12.00K |
| Earnings from Continuing Operations | -57.53 | -27.19 | -14.11 | -11.30 | -9.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.53M | -27.19M | -14.11M | -11.30M | -9.99M |
| EBIT | -34.07M | -29.47M | -15.08M | -12.14M | -10.56M |
| EBITDA | -34.07M | -29.47M | -15.07M | -12.13M | -10.56M |
| EPS Basic | -2.04 | -1.09 | -0.54 | -0.48 | -0.46 |
| Normalized Basic EPS | -0.70 | -0.68 | -0.34 | -0.30 | -0.29 |
| EPS Diluted | -2.04 | -1.09 | -0.55 | -0.49 | -0.47 |
| Normalized Diluted EPS | -0.70 | -0.68 | -0.34 | -0.30 | -0.29 |
| Average Basic Shares Outstanding | 106.85M | 99.49M | 94.79M | 89.92M | 86.34M |
| Average Diluted Shares Outstanding | 106.85M | 99.49M | 95.75M | 90.88M | 87.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |